Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Penumbra, Inc.
Depomed Inc (NASDAQ: DEPO) announced Thursday that it will acquire the U.S. rights to the NUCYNTA franchise from Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Pharmaceuticals, Inc. for $1.05 billion. According to the company’s press release, “The NUCYNTA franchise. Read More. Don t Miss Any Updates! News Directly in Your Inbox Subscribe to:
Is ARWR A Good Stock To Buy Now According To Hedge Funds?
The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive review of these public filings is finally over, so this article is set to reveal the smart money sentiment towards Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR).
Is ARWR a good stock to buy now? Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) shareholders have witnessed an increase in hedge fund sentiment in recent months. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) was in 22 hedge funds’ portfolios at the end of the third quarter of 2020. The all time high for this statistic is 26. There were 21 hedge funds in our database with ARWR holdings at the end of June. Our calculations als
This press release was orginally distributed by SBWire
Edison, NJ (SBWIRE) 12/18/2020 The latest 114+ page survey report on COVID-19 Outbreak-Global RNA-Based Therapeutics and Vaccines Market is released by HTF MI covering various players of the industry selected from global geographies like North America (Covered in Chapter 7 and 14), United States, Canada, Mexico, Europe (Covered in Chapter 8 and 14), Germany, UK, France, Italy, Spain, Russia, Others, Asia-Pacific (Covered in Chapter 9 and 14), China, Japan, South Korea, Australia, India, Southeast Asia, Others, Middle East and Africa (Covered in Chapter 10 and 14), Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Others, South America (Covered in Chapter 11 and 14), Brazil, Argentina, Columbia, Chile & Others. A perfect mix of quantitative & qualitative Market information highlighting developments, industry challenges that competitors are facing along with gaps and opportunity available and would trend in COVID-19 Outbreak
Edison, NJ (SBWIRE) 12/18/2020 The latest 114+ page survey report on COVID-19 Outbreak-Global RNA-Based Therapeutics and Vaccines Market is released by HTF MI covering various players of the industry selected from global geographies like North America (Covered in Chapter 7 and 14), United States, Canada, Mexico, Europe (Covered in Chapter 8 and 14), Germany, UK, France, Italy, Spain, Russia, Others, Asia-Pacific (Covered in Chapter 9 and 14), China, Japan, South Korea, Australia, India, Southeast Asia, Others, Middle East and Africa (Covered in Chapter 10 and 14), Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Others, South America (Covered in Chapter 11 and 14), Brazil, Argentina, Columbia, Chile & Others. A perfect mix of quantitative & qualitative Market information highlighting developments, industry challenges that competitors are facing along with gaps and opportunity available and would trend in COVID-19 Outbreak- RNA-Based Therapeutics and Vaccines market. The st